News Briefs: Wegovy Gains Another Indication

The FDA on March 8 granted Novo Nordisk A/S’s Wegovy (semaglutide) yet another indication — for cardiovascular risk reduction — that could further boost staggering GLP-1 sales. Wegovy is now approved to reduce risk of “major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke” in adults who are either overweight or obese and have established cardiovascular disease, per a Novo press release. FDA official John Sharretts, M.D., described Wegovy as the first weight loss medication “to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight.” As the FDA noted in a press release, approximately 70% of U.S. adults are obese or overweight. The new indication was approved after a priority review.

© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

optum
February 8

Direct-to-Consumer Prescribing Could Have Downsides

READ MORE
insulin-injection
January 11

Commercial Payers Wrestle With Managing Weight Loss Drug Coverage

READ MORE
lilly-corporate-hq
January 11

Lilly’s Direct-to-Consumer GLP-1 Service Likely Doesn’t Threaten PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today